Bleakley Financial Group LLC purchased a new position in shares of Unicycive Therapeutics, Inc. (NASDAQ:UNCY – Free Report) in the third quarter, Holdings Channel.com reports. The firm purchased 80,000 shares of the company’s stock, valued at approximately $33,000.
Separately, Virtu Financial LLC purchased a new stake in shares of Unicycive Therapeutics in the 1st quarter valued at about $36,000. Institutional investors and hedge funds own 40.42% of the company’s stock.
Analyst Ratings Changes
Several analysts have commented on the company. HC Wainwright reaffirmed a “buy” rating and set a $2.50 price objective on shares of Unicycive Therapeutics in a research note on Wednesday, October 9th. Brookline Capital Management raised Unicycive Therapeutics to a “strong-buy” rating in a research note on Tuesday, July 9th. Finally, Benchmark reissued a “speculative buy” rating and set a $3.00 target price on shares of Unicycive Therapeutics in a research note on Friday, September 6th. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $5.13.
Unicycive Therapeutics Price Performance
NASDAQ UNCY opened at $0.42 on Friday. Unicycive Therapeutics, Inc. has a 1-year low of $0.20 and a 1-year high of $1.82. The company has a market capitalization of $39.41 million, a P/E ratio of -0.40 and a beta of 2.36. The business has a 50 day moving average price of $0.38 and a 200 day moving average price of $0.63.
Unicycive Therapeutics (NASDAQ:UNCY – Get Free Report) last released its quarterly earnings data on Wednesday, August 14th. The company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.08. On average, research analysts expect that Unicycive Therapeutics, Inc. will post -0.26 earnings per share for the current fiscal year.
Unicycive Therapeutics Company Profile
Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.
Featured Articles
- Five stocks we like better than Unicycive Therapeutics
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Why Meta’s Pre-Earnings Dip Could Be A Golden Entry Opportunity
- What does consumer price index measure?
- Spirit Airlines Stock Nearly Doubled: Are Clear Skies Ahead?
- How to Invest in Tech StocksĀ and Top Tech Stocks to Consider
- Tesla Stock: Buy the Dips, Sell the Rips
Want to see what other hedge funds are holding UNCY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Unicycive Therapeutics, Inc. (NASDAQ:UNCY – Free Report).
Receive News & Ratings for Unicycive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unicycive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.